Free Trial
NASDAQ:ICCM

IceCure Medical Q2 2026 Earnings Results & Report

IceCure Medical logo
$1.10 -0.03 (-2.65%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.14 +0.04 (+4.09%)
As of 10/9/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IceCure Medical reported Q2 2026 earnings on June 30, 2026. The company reported EPS of -$1.60, while revenue was $0.91 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

IceCure Medical EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

IceCure Medical Revenue Results

Actual Revenue
$0.91 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

IceCure Medical's Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled at 10:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

IceCure Medical Q2 2026 Earnings FAQ

IceCure Medical (NASDAQ:ICCM) reported earnings of -$1.60 per share for Q2 2026. The report was announced on Tuesday, June 30, 2026.

IceCure Medical reported revenue of $0.91 million for Q2 2026.

IceCure Medical's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for IceCure Medical on the company's earnings history page.

IceCure Medical Earnings Headlines

Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
See More IceCure Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email.

About IceCure Medical

IceCure Medical (NASDAQ:ICCM) (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance. The system and its related technologies are subject to regulatory clearances and approvals that vary by country and by intended use.

IceCure was founded in Israel and serves healthcare providers and medical markets internationally. The company has supported clinical studies and commercial activities in the United States, Israel, Europe, and other regions as it seeks to expand the use of cryoablation in oncology. Its shares began trading on the Nasdaq Capital Market in 2021.

View IceCure Medical Profile